Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

NCT06937177 is registered in ClinicalTrials.gov with Endevica Bio as lead sponsor.

NCT NCT06937177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Lead sponsor
Endevica Bio
Phase
Phase 2
Overall status
Recruiting
Start date
April 28, 2025
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cancer weight loss